UnitedHealth Group Incorporated (NYSE:UNH) reported its Q1 results, with EPS of $5.49 coming in better than the Street expectations of $5.37. The slight outperformance was driven by the Optum segment. The company raised its full 2022-year EPS guidance to $21.20-$21.70 (vs. Street $21.60) from $21.10-$21.60 prior, with "just under 50%" of earnings expected H1/22.

Analysts at Oppenheimer provided their views on the company following the results, raising their 2022/2023/2024 EPS estimates to $21.68/$24.54/$27.84 from $21.57/$24.54/$27.76 and their price target to $600 from $550.

Overall, the analysts believe the results were solid, slightly topping expectations as the company continually produces steady and consistent results despite an ever-changing environment.